Ambrosia Biosciences secured an oversubscribed $100 million Series B to advance its oral obesity drug pipeline, including a lead small-molecule GLP-1 candidate. The funding, co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital, supports moving the lead program into Phase I and expanding additional metabolic targets including GIP and amylin. The startup was formed after Pfizer shuttered an R&D facility following its 2019 acquisition of Array BioPharma. In its funding release, Ambrosia framed the round as validation for combinable oral small molecules as competition heats up after oral GLP-1 approvals. Strategically, the company’s approach—structural biology and computational chemistry to build orally bioavailable GPCR modulators—targets gaps left by first-generation incretin molecules, according to management commentary. For investors and BD teams, the round adds another credible entrant to the post-injectable oral obesity landscape, where differentiation increasingly depends on safety, tolerability, and combination positioning rather than single-agent weight-loss magnitude.